Press "Enter" to skip to content

PRESS RELEASE NORTH CHICAGO.

Imbruvica® is a Bruton's tyrosine kinase inhibitor approved for use in four indications to treat three different types of blood cancers including chronic lymphocytic leukemia, mantle cell lymphoma and Waldenstrom's macroglobulinemia. Imbruvica® received initial U.S. Meals and Drug Administration authorization in 2013 and may be the only therapy to have received three Breakthrough Therapy designations by the FDA. It is currently approved in more than 40 countries. Significant opportunity exists with additional Imbruvica® indications, including solid tumors, the potential to leverage AbbVie's immunology knowledge for the advancement of Pharmacyclics' immunology program, and advance AbbVie's attempts in hematologic malignancies.Our competition is certainly fierce, and so we have to take every benefit we can get. The AIDS epidemic among adults in the usa is an increasing concern, with HIV illness the seventh leading cause of death among those 13 to 24, according to the National Institutes of Wellness. Compounding the problem is certainly a common feeling among adolescents they are invincible, which may cause them to take part in risky behavior, based on the NIH. In today’s study, Co-researcher and Noland Robert McDermott, a professor of wellness education at the University of South Florida, asked 88 men and 85 women, average age 19, to rate each of 15 adjective pairs describing condoms on a seven-point scale from most favorable to least favorable.